
A popular asthma inhaler is being discontinued Jan. 1, fueling concerns that patients may have trouble getting insurance coverage for alternatives. GSK, maker of the branded inhaler Flovent, will make “an authorized generic” version of the drug, but without the same branding. While doctors say it will work just as well, it doesn’t appear to be as widely covered by insurance, according to CNN. As a result, patients may be forced to get new new prescriptions and iron out insurance coverage at the peak of respiratory virus season. “This medication has been the most commonly used inhaled medication for the past 25 or 30 years,” Dr. Robyn Cohen, director of the Pediatric Pulmonary and Allergy Clinic at Boston Medical Center, told CNN. “It’s the one that, overwhelmingly, pediatricians reach for when they decide that their patient needs a daily preventive medication. … The fact that it’s being discontinued is going to be a huge shock to the system for patients, for families and for doctors.” Doctors urge patients to make sure they’ve got medicine lined up as the calendar turns to 2024. A GSK spokeswoman told CNN the company is making the change “as part of our commitment to be ambitious for patients.” She noted the company introduced the authorized generics of Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder, in 2022… read on > read on >